{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341206","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-08-10T11:05:20+00:00","discovered_at":"2026-08-10T11:10:00.481591+00:00","generated_at":"2026-08-10T11:10:22.019388+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome Q2 2026 revenue up 46% to $218.4M; AUVELITY Alzheimer's launch underway","bullets":["Total net product revenue $218.4M, +46% YoY; AUVELITY sales $180.3M (+51% YoY), SUNOSI $35.8M (+20%), SYMBRAVO $2.3M (+461%).","Net loss $51.3M ($0.99/share) vs $48.0M loss ($0.97) in Q2 2025; SG&A up to $208.1M from $130.3M on launch activities.","AUVELITY launched for Alzheimer's disease agitation in June 2026; new-to-brand Rx +126% in patients ≥65 in first 8 weeks.","NDA for AXS-12 (cataplexy in narcolepsy) accepted by FDA; PDUFA target action date May 1, 2027.","Cash $319.9M at June 30, 2026; guidance says sufficient to fund operations into cash flow positivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341206","json":"https://secwatch.observer/filing/0001193125-26-341206.json","markdown":"https://secwatch.observer/filing/0001193125-26-341206.md","text":"https://secwatch.observer/filing/0001193125-26-341206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/0001193125-26-341206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:10:22.019388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}